Article Figures & Data
Figures
- FIGURE 1.
18F-FLT biodistribution (%ID/g) in male and female 129S6/SvEv (A), athymic nude (B), and BALB/c (C) mice sacrificed 1 and 2 h after injection of 0.74–0.89 MBq (20–24 μCi) of 18F-FLT (n = 5 129S6/SvEv, 5 athymic nude, and 4 BALB/c mice per time point). *P < 0.05 (male vs. female for each tissue).
- FIGURE 2.
18F-FLT PET/CT maximal-intensity-projection images of representative female (n = 3) and male (n = 3) athymic nude mice scanned concurrently 1 h after injection of 0.93 MBq (25 μCi) of 18F-FLT.
- FIGURE 3.
Time–activity curves for 18F-FLT in male and female athymic nude mice imaged using dynamic PET from 0 to 60 min after injection of approximately 0.93 MBq (25 μCi) of 18F-FLT. Regions of interest were drawn, and time–activity curves determined, for urinary bladder (A), kidney (B), blood (C), liver (D), bone (E), and muscle (F).
- FIGURE 4.
18F-FDG biodistribution (%ID/g) in male and female 129S6/SvEv mice sacrificed 1 and 2 h after injection of 0.74 MBq (20 μCi) of 18F-FDG (n = 5 per group). *P < 0.05 (male vs. female for each tissue).
- FIGURE 5.
18F-FLT biodistribution (T:M %ID/g) in SSM3 mammary tumor–bearing and CWR22 prostate cancer xenograft–bearing mice sacrificed 1 h (n = 5 SSM3 and 4 CWR22) and 2 h (n = 5 SSM3 and 5 CWR22) after injection of 0.85 MBq (23 μCi) of 18F-FLT. *P < 0.05 (CWR22 vs. SSM3 tumors).
- FIGURE 6.
(A) 18F-FLT biodistribution (tumor [T] and muscle [M] %ID/g) in female (n = 5) and male (n = 5) mice bearing hormone-independent, estrogen receptor–negative MDA-MB-231 human breast cancer cells and sacrificed 2 h after injection of 0.67–0.78 MBq (18–21 μCi) of 18F-FLT. *P < 0.05 (tumor vs. muscle). #P < 0.05 (female tumor vs. male tumor). (B) Representative Ki-67 immunohistochemistry of MDA-MB-231 tumors (×40).
Additional Files
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- No citing articles found.